Business & Finance
Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea
26 November 2021 - - South Korea-based Enzychem Lifesciences (KOSDAQ: 183490) and India-based Cadila Healthcare Ltd, a part of the Zydus Group, have entered a Manufacturing License and Technology Transfer Agreement for the world's first plasmid DNA vaccine (ZyCoV-D), the companies said.

Following the results of a large clinical trial involving nearly 30,000 subjects, ZyCoV-D was recently granted emergency use approval by India's national regulatory agency for subjects 12 years and above.

Under the terms of this agreement, Zydus shall transfer its manufacturing technology and provide technical assistance to Enzychem.

Both CHL and Enzychem believe that this partnership will lead to estimated manufacturing of 80m or more doses of the plasmid DNA vaccine in 2022.

Accordingly, Enzychem shall pay Zydus license fees and royalties for the commercialization of the Plasmid DNA-based COVID-19 vaccine made in Korea and exported to a number of countries, including low-medium income countries (LMICs) in Latin America and Asian New Southern Policy member countries.

Headquartered in Seoul, South Korea, Enzychem Lifesciences (KOSDAQ: 183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases.

Enzychem lead candidate, EC-18, has successfully completed US FDA phase 2 clinical testing in cancer patients.

In response to the Korean government pledge for a Vaccine Hub, Enzychem has formed a consortium with Hanmi Pharma and several domestic companies in Korea to manufacture vaccines against COVID 19.

The company plans to leverage its expertise in lipid chemistry and manufacturing to establish itself as a regional producer of lipid-based formulations for improved delivery of nucleic acids and other biologicals and drugs.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.